BioSpace News Archive

Business

ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies

ASLAN Pharmaceuticals and Thermo Fisher Scientific Inc (NYSE: TMO), the world leader in serving science, today announced a partnership to manufacture a high concentration formulation of eblasakimab for Phase 3 clinical trials.

January 3, 2023
·
6 min read
Pharm Country

Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences Ltd. today announced that the second patient (“EA2”) with non-active secondary progressive multiple sclerosis (SPMS) receiving intranasal foralumab has shown additional clinical improvements since their last reported improvement in September 2022.

January 3, 2023
·
4 min read
Drug Development

ProfoundBio Announces Initiation of First-in-Human Trial for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload

ProfoundBio announced that 1) dosing has initiated in the Phase 1 first-in-human clinical trial of PRO1184 (NCT05579366), and 2) the company received clearance from the U.S. Food and Drug Administration (FDA) to initiate the Phase 1 clinical trial evaluating PRO1160.

January 3, 2023
·
3 min read
FDA

HotSpot Therapeutics Announces FDA Clearance of IND Application for HST-1011, An Investigational Small Molecule Allosteric Inhibitor of CBL-B

HotSpot Therapeutics, Inc. today announced the clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for HST-1011, the Company’s investigational small molecule allosteric inhibitor of casitas B-lineage lymphoma-B (CBL-B).

January 3, 2023
·
3 min read
CollPlant Enriches Portfolio of rhCollagen-Based Bioinks with Launch of Collink.3DTM 50L in Powder Form

CollPlant today announced the launch of Collink.3DTM 50L, a recombinant human collagen (rhCollagen)-based bioink in a powder form for use in a wide range of 3D bioprinting applications, including drug discovery, drug screening, tissue testing as well as the development of transplantable tissues and organs.

January 3, 2023
·
6 min read
Drug Development

RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced publication of positive data from a Phase 2 study of once-daily oral investigational RHB-107 (upamostat)[2] in non-hospitalized symptomatic COVID-19 patients.

January 3, 2023
·
10 min read
Business

Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York

Bristol Myers Squibb (NYSE: BMY ) has completed the previously announced sale of its manufacturing facility in Syracuse, New York to LOTTE BIOLOGICS.

January 3, 2023
·
2 min read
Genetown

Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 9:45 AM PT.

January 3, 2023
·
1 min read
Genetown

AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference

AlloVir, Inc. today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 10, 2023, at 2:15 p.m. PST.

January 3, 2023
·
1 min read
Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Silence Therapeutics plc today announced that Craig Tooman, President and Chief Executive Officer of Silence, will present at the 41st Annual J.P. Morgan Healthcare Conference.

January 3, 2023
·
1 min read